J&J is looking to add a hormone-sensitive indication to its prostate cancer therapy, which was originally approved in 2023.

Molecular profiling could reduce both overtreatment and undertreatment of patients with high-intermediate risk endometrial ...

J&J has rights to niraparib in prostate cancer, and views the drug as a successor to Zytiga, once a $2.5 billion-a-year ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced data from a colorectal ...

Biomodal reports methylation sequencing is expanding the window for early detection.

A University of Alberta research team has identified a DNA structure that activates the immune system in cancer cells that ...

In a multi-institutional study published in Science Direct, researchers revealed that testing urine-based tumor DNA (utDNA) ...

Investigating how mutations in tumors alter DNA’s 3D structure—and subsequently, regulatory sequences called enhancers—can ...

Scientists have identified two proteins involved in regulating chromatin remodelling which could be promising therapeutic ...

June brought major breast cancer updates, and CURE is sharing the latest treatment combinations, biomarker-driven care and ...

Almost all cervical cancers are caused by human papillomaviruses (HPVs). In most cases, HPV DNA is integrated into the human genome. We found that tumor-specific, HPV-human DNA junctions are ...